Mitchell, Helen
Mclean, Jennifer
Gavin, Anna T
Visser, Otto
Millar, Elinor
Luff, Tessa
Bennett, Damien
Article History
Received: 26 April 2023
Accepted: 24 July 2023
First Online: 26 July 2023
Declarations
:
: The authors declare that they have no competing interests.
: This study was conducted on aggregate anonymised data in with data sharing agreements in place with New Zealand and the Netherlands and data is presented in accordance with Northern Ireland Cancer Registry (NICR) Confidentiality and Data Protection Policies and New Zealand’s Privacy Act 2020, the Health Information Privacy Code 2020. The NICR has ethical approval from the Office for Research Ethics Committees of Northern Ireland (ORECNI) (Ref: 20/NI/0132, IRAS project ID: 288121), for the collection and use of routinely collected data, relating to cancer patients, within the fields of health and social care research. As such, specific ethical approval and informed consent from the data subjects were not required for this study. All methods were subject to scientific critique and all data processing and analysis was conducted in accordance with the ORECNI conditions for ethical approval to use this data. The data from New Zealand was provided at an aggregated level in adherence to New Zealand’s Privacy Act 2020, the Health Information Privacy Code 2020, and the Health Information Governance Guidelines Ministry of Health, HISO 10064:2017: health information governance guidelines. Wellington, New Zealand: Ministry of Health; 2017. As such, ethical approval was not required from an ethics committee in New Zealand and the aggregate anonymous data was approved for use in line with Te Aho o Te Kahu Confidentiality and Data Protection Policies. In the Netherlands, this study did not require approval from an ethics committee according to the Central Committee on Research involving Human Subjects (CCMO). The Privacy Review Board of the Netherlands Cancer Registry approved the use of anonymous data for this study.
: Not applicable.